View Future GrowthAthenex 과거 순이익 실적과거 기준 점검 0/6Athenex 의 수입은 연평균 -7.6%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 11.2%의 비율로 증가해 왔습니다.핵심 정보-7.61%순이익 성장률9.17%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률11.15%자기자본이익률n/a순이익률-95.29%최근 순이익 업데이트31 Dec 2022최근 과거 실적 업데이트Reported Earnings • Nov 04Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.14 loss per share (improved from US$0.33 loss in 3Q 2021). Revenue: US$33.5m (up 3.8% from 3Q 2021). Net loss: US$19.4m (loss narrowed 46% from 3Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 6.7%. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.Reported Earnings • Jul 28Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)Second quarter 2022 results: US$0.21 loss per share (up from US$0.33 loss in 2Q 2021). Revenue: US$31.5m (up 44% from 2Q 2021). Net loss: US$23.8m (loss narrowed 31% from 2Q 2021). Over the next year, revenue is forecast to grow 8.2%, compared to a 40% growth forecast for the industry in the US.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.16 loss per share. Revenue: US$29.7m (down 28% from 1Q 2021). Net loss: US$30.0m (loss widened 20% from 1Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 9.0%, compared to a 48% growth forecast for the industry in the US.Reported Earnings • Mar 19Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$1.85 loss per share (down from US$1.67 loss in FY 2020). Revenue: US$120.2m (down 17% from FY 2020). Net loss: US$192.0m (loss widened 35% from FY 2020). Products in clinical trials Phase I: 5 Phase II: 1 Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 43%. Over the next year, revenue is expected to shrink by 4.4% compared to a 64% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$32.3m (down 9.0% from 3Q 2020). Net loss: US$36.1m (loss narrowed 2.0% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$21.9m (down 45% from 2Q 2020). Net loss: US$34.3m (loss narrowed 15% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • Aug 18+ 1 more updateAthenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring OfficerAthenex, Inc. announced that on August 11, 2023, Joe Annoni, Chief Financial Officer and Assistant Chief Restructuring Officer of the company, and the Company mutually agreed that Mr. Annoni would separate from the Company effective immediately.공시 • Jul 08Nasdaq to Delist the Common Stock of AthenexNasdaq also announced on July 06, 2023 that it will delist the common stock of Athenex, Inc. The company’s securities were suspended on April 13, 2023, and have not traded on Nasdaq since that time.공시 • May 26Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite IndexAthenex, Inc. has been dropped from NASDAQ Composite Index.공시 • May 25Athenex, Inc. announced delayed 10-Q filingOn 05/23/2023, Athenex, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 24Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 CaseOn May 16, 2023, Athenex, Inc. received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, as a result of the Chapter 11 Case and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Nasdaq staff determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on May 25, 2023.공시 • May 18Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI IndexAthenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index공시 • May 15+ 2 more updatesMotion for Asset Sale Filed by Athenex, Inc.Athenex, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on May 14, 2023. The debtor seeks the Court’s approval for the sale of its substantially all its assets to the stalking horse bidder. The debtor shall designate stalking horse bidder on June 2, 2023. To qualify as a qualified bidder, interested parties should submit their bids by June 12, 2023, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.10 million more than the initial purchase price. The debtor has scheduled an auction on June 15, 2023. At the auction, the subsequent bids would be in increments of $0.1 million. The stalking horse bidder would be entitled to a break-up fee of 3% of the cash portion of the purchase price and expense reimbursement of 1% of the cash portion of the purchase price in case of termination of the asset purchase agreement. The sale hearing is scheduled for June 21, 2023. Sale closing shall occur on June 30, 2023공시 • May 05Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)On April 27, 2023, Athenex, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days and its number of publicly held shares, the Company no longer meets Nasdaq Listing Rule 5450(b)(3)(C), which requires listed companies to maintain a minimum market value of publicly held shares of at least $15 million. Nasdaq Listing Rule 5810(c)(3)(D) provides a compliance period of 180 calendar days, or until October 24, 2023, in which to regain compliance with this requirement. If the Company’s market value of publicly held shares is $15 million or more for a minimum of 10 consecutive business days during the 180-day compliance period, Nasdaq will provide written notice of compliance to the Company. If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The notification has no immediate effect on the listing of the Company’s common stock on Nasdaq’s Global Select Market. The Company intends to monitor the closing bid price of its common stock and its number of publicly held shares and consider its available options in the event the market value of its publicly held shares remains below $15 million.공시 • Feb 17Athenex Announces Reverse Stock SplitAthenex, Inc. announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. The Company's Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of The Nasdaq Global Select Market. The Company has until March 14, 2023 to comply with this requirement. To evidence compliance with this requirement, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days by March 14, 2023. The Company's shares of common stock will continue to trade on The Nasdaq Global Select Market under the symbol "ATNX." The new CUSIP number for the Company's common stock post-reverse stock split is 04685N202.공시 • Jan 04Athenex Announces MHRA Decision on Oral PaclitaxelAthenex, Inc. announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for metastatic breast cancer based solely on CMC issues. The MHRA application was not rejected based on any clinical efficacy or safety concerns expressed by the MHRA. MHRA regulations allow an applicant to request a re-examination of an opinion by an independent board which the Company plans to pursue. The Company views the identified CMC issues as addressable.Price Target Changed • Nov 16Price target decreased to US$2.17Down from US$2.33, the current price target is an average from 3 analysts. New target price is 965% above last closing price of US$0.20. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$0.66 next year compared to a net loss per share of US$1.85 last year.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 04Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.14 loss per share (improved from US$0.33 loss in 3Q 2021). Revenue: US$33.5m (up 3.8% from 3Q 2021). Net loss: US$19.4m (loss narrowed 46% from 3Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 6.7%. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.Seeking Alpha • Aug 11Athenex prices $30M in stock and warrants offeringAthenex (NASDAQ:ATNX) plunged 23.9% down premarket after it priced its underwritten public offering of 35.3M shares and accompanying warrants at a combined public offering price of $0.75/share and accompanying warrant, pre-funded warrants to purchase up to 4.67M shares at a combined public offering price of $0.749/share and accompanying warrant. Gross proceeds are expected to be ~$30M. Offer is expected to close on Aug.15, 2022. Net proceeds was used to fund ongoing clinical development for its product candidates and for working capital and other general corporate purposes.Seeking Alpha • Aug 05Athenex surges 70% as Dr Reddy's and Intas race to form buyout dealThe shares of Athenex Inc. (NASDAQ:ATNX) climbed ~70% on rising volumes in the post-market Thursday in reaction to reports that India's Dr. Reddy's Laboratories (RDY) and Intas Pharmaceuticals are in talks to acquire the cancer-focused biotech. The companies are competing against several mid-market healthcare-focused U.S. private equity funds to strike a deal as the biotech looks to sell a controlling stake, India's The Economic Times newspaper reported citing people with knowledge of the matter. The clinical-stage biotech is said to have named Cowen to lead a formal process to find an acquirer. "A formal process has started, and the first round of offers have come in," one of the people said. "Intas and Dr. Reddy's are the two Indian firms in the race at present. A transaction could be concluded during the current quarter." Athenex (ATNX) is the latest biotech to generate reports of buyout interest on Thursday. Before the market open, Amgen (AMGN) announced an agreement to acquire ChemoCentryx (CCXI) for $3.7B in cash.Reported Earnings • Jul 28Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)Second quarter 2022 results: US$0.21 loss per share (up from US$0.33 loss in 2Q 2021). Revenue: US$31.5m (up 44% from 2Q 2021). Net loss: US$23.8m (loss narrowed 31% from 2Q 2021). Over the next year, revenue is forecast to grow 8.2%, compared to a 40% growth forecast for the industry in the US.Seeking Alpha • Jul 28Athenex GAAP EPS, revenue misses estimatesAthenex press release (NASDAQ:ATNX): Q2 GAAP EPS of -$0.28 misses by $0.13. Revenue of $25.79M (+17.7% Y/Y) misses by $5.47M. Shares +5% PM. Athenex continues to expect product sales from continuing operations growth to be in the range of 20-25% over the prior year period.Seeking Alpha • Jul 11Athenex to sell its China API business for $19MAthenex (NASDAQ:ATNX) and certain affiliates to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient (API) manufacturing operations, to TiHe Capital Co., Ltd. for RMB 124.4 million, or ~$19M. Athenex will receive at least 70% of the proceeds at closing, followed by 20% within three months after the closing date, and the remaining balance within six months after the closing date. The proceeds will be used in part toward repaying existing debt and operating the business. The deal is subject to customary closing conditions Athenex and TiHe also plan to enter into a long-term supply agreement for the manufacture and supply of certain API products. The company continues to monetize non-core assets to extend cash runway. ATNX --3.1563845% after hours to $0.54 Source: Press ReleaseBoard Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.16 loss per share. Revenue: US$29.7m (down 28% from 1Q 2021). Net loss: US$30.0m (loss widened 20% from 1Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 9.0%, compared to a 48% growth forecast for the industry in the US.Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Apr 27Price target decreased to US$4.50Down from US$5.25, the current price target is an average from 5 analysts. New target price is 765% above last closing price of US$0.52. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$0.49 next year compared to a net loss per share of US$1.85 last year.Price Target Changed • Apr 13Price target decreased to US$4.50Down from US$5.40, the current price target is an average from 4 analysts. New target price is 552% above last closing price of US$0.69. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$0.51 next year compared to a net loss per share of US$1.85 last year.Major Estimate Revision • Mar 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$135.3m to US$114.9m. EPS estimate increased from -US$1.01 to -US$0.55 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$6.25 to US$5.50. Share price rose 16% to US$0.99 over the past week.Reported Earnings • Mar 19Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$1.85 loss per share (down from US$1.67 loss in FY 2020). Revenue: US$120.2m (down 17% from FY 2020). Net loss: US$192.0m (loss widened 35% from FY 2020). Products in clinical trials Phase I: 5 Phase II: 1 Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 43%. Over the next year, revenue is expected to shrink by 4.4% compared to a 64% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 18Price target decreased to US$5.50Down from US$6.25, the current price target is an average from 4 analysts. New target price is 479% above last closing price of US$0.95. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$1.85 last year.Price Target Changed • Feb 24Price target increased to US$6.67Up from US$5.60, the current price target is an average from 3 analysts. New target price is 726% above last closing price of US$0.81. Stock is down 93% over the past year. The company is forecast to post a net loss per share of US$1.34 next year compared to a net loss per share of US$1.72 last year.Recent Insider Transactions • Nov 20Independent Director recently bought US$61k worth of stockOn the 17th of November, Jinn Wu bought around 30k shares on-market at roughly US$2.03 per share. In the last 3 months, they made an even bigger purchase worth US$161k. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$32.3m (down 9.0% from 3Q 2020). Net loss: US$36.1m (loss narrowed 2.0% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 15Independent Director recently bought US$161k worth of stockOn the 14th of September, Jinn Wu bought around 50k shares on-market at roughly US$3.22 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.Seeking Alpha • Aug 31Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers. Athenex's pipeline consists of four therapeutic programs, Orascovery (P-glycoprotein pump inhibitor), Src Kinase Inhibition, Cell Therapy, and Arginine Deprivation Therapy. Athenex's lead therapeutic is Klisyri (tirbanibulin) launched in the US in Feb 2021 with an EU launch expected in 2H’21 under a partnership with Almirall. Athenex received a CRL from the FDA in Feb'21 for Oral paclitaxel + encequidar's and now Athenex is planning a new study design expected to be presented in 4Q 2021. In summary, the author projects Athenex, Inc. as a "hold".Executive Departure • Aug 18Chief Financial Officer Randoll Sze has left the companyOn the 13th of August, Randoll Sze's tenure as Chief Financial Officer ended after 3.0 years in the role. As of June 2021, Randoll still personally held only 6.00k shares (US$28k worth at the time). Randoll is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.42 years.Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$21.9m (down 45% from 2Q 2020). Net loss: US$34.3m (loss narrowed 15% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Major Estimate Revision • Aug 06Consensus EPS estimates fall to -US$1.31The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from US$124.5m to US$120.9m. Losses expected to increase from -US$1.14 to -US$1.31. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$7.95 to US$7.33. Share price fell 4.5% to US$3.60 over the past week.Price Target Changed • Jul 07Price target decreased to US$7.50Down from US$8.67, the current price target is an average from 8 analysts. New target price is 86% above last closing price of US$4.03. Stock is down 70% over the past year.Reported Earnings • May 11First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$41.0m (down 13% from 1Q 2020). Net loss: US$25.1m (loss widened 29% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Recent Insider Transactions Derivative • May 07Independent Director exercised options to buy US$230k worth of stock.On the 5th of May, Jinn Wu exercised options to buy 50k shares at a strike price of around US$4.55, costing a total of US$228k. This transaction amounted to 16% of their direct individual holding at the time of the trade. Since June 2020, Jinn's direct individual holding has decreased from 371.21k shares to 303.21k. Company insiders have collectively sold US$342k more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • May 07Consensus EPS estimates increase to -US$1.42The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$115.2m to US$120.9m. EPS estimate increased from -US$1.74 to -US$1.42. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target of US$8.67 unchanged from last update. Share price rose 15% to US$4.60 over the past week.분석 기사 • Apr 04Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Recent Insider Transactions Derivative • Mar 20Chairman & CEO exercised options to buy US$98k worth of stock.On the 19th of March, Yiu-Nam Lau exercised options to buy 20k shares at a strike price of around US$4.55, costing a total of US$91k. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since March 2020, Yiu-Nam's direct individual holding has increased from 3.28m shares to 3.33m. Company insiders have collectively sold US$380k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Mar 11Insider recently sold US$1.9m worth of stockOn the 4th of March, Wei Zuo sold around 420k shares on-market at roughly US$4.52 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$560k more than they bought in the last 12 months.분석 기사 • Mar 09Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?Some Athenex, Inc. ( NASDAQ:ATNX ) shareholders may be a little concerned to see that insider Wei Zuo recently sold a...Major Estimate Revision • Mar 08Analysts lower revenue estimates to US$115.2mThe 2021 consensus revenue estimate decreased from US$178.3m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.18 to -US$1.47 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 4.8% next year. The consensus price target was lowered from US$27.41 to US$10.00. Share price is down by 64% to US$4.32 over the past week.분석 기사 • Mar 06These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS ForecastsOne thing we could say about the analysts on Athenex, Inc. ( NASDAQ:ATNX ) - they aren't optimistic, having just made a...Recent Insider Transactions • Mar 05Independent Director recently sold US$466k worth of stockOn the 3rd of March, Jinn Wu sold around 98k shares on-market at roughly US$4.75 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$1.9m more than they sold in the last 12 months.Reported Earnings • Mar 03Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$144.4m (up 43% from FY 2019). Net loss: US$146.2m (loss widened 18% from FY 2019). Post-clinical trial products Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 03Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 5.8%. Earnings per share (EPS) also surpassed analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 4.0% compared to a 1,173% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Mar 02New 90-day low: US$5.46The company is down 59% from its price of US$13.30 on 01 December 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$80.60 per share.Price Target Changed • Mar 02Price target lowered to US$24.78Down from US$27.74, the current price target is an average from 9 analysts. The new target price is 354% above the current share price of US$5.46. As of last close, the stock is down 58% over the past year.분석 기사 • Feb 19Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...분석 기사 • Jan 29When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?With the business potentially at an important milestone, we thought we'd take a closer look at Athenex, Inc.'s...매출 및 비용 세부 내역Athenex가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:ATNX.Q 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 22103-98495230 Sep 22123-178705630 Jun 22121-192716531 Mar 22109-198677131 Dec 2195-158577830 Sep 21113-132757830 Jun 21117-135837931 Mar 21137-144868031 Dec 20144-142937630 Sep 20157-118847930 Jun 20141-116788031 Mar 20123-1087710131 Dec 19101-123668430 Sep 1988-129606530 Jun 1987-141554631 Mar 1977-14551331 Dec 1889-1174912030 Sep 1883-11950030 Jun 1878-9649031 Mar 1871-9749031 Dec 1738-13146230 Sep 1728-14344030 Jun 1720-14440031 Mar 1721-11831031 Dec 1621-8826030 Sep 1621-6121031 Dec 1514-5126031 Dec 141-1852양질의 수익: ATNX.Q 은(는) 현재 수익성이 없습니다.이익 마진 증가: ATNX.Q는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ATNX.Q은 수익성이 없으며 지난 5년 동안 손실이 연평균 7.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ATNX.Q의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ATNX.Q은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ATNX.Q의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/10/04 12:55종가2023/10/02 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Athenex, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jack HuDeutsche BankUmer RaffatEvercore ISIJialin ZhangICBC International Research8명의 분석가 더 보기
Reported Earnings • Nov 04Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.14 loss per share (improved from US$0.33 loss in 3Q 2021). Revenue: US$33.5m (up 3.8% from 3Q 2021). Net loss: US$19.4m (loss narrowed 46% from 3Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 6.7%. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
Reported Earnings • Jul 28Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)Second quarter 2022 results: US$0.21 loss per share (up from US$0.33 loss in 2Q 2021). Revenue: US$31.5m (up 44% from 2Q 2021). Net loss: US$23.8m (loss narrowed 31% from 2Q 2021). Over the next year, revenue is forecast to grow 8.2%, compared to a 40% growth forecast for the industry in the US.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.16 loss per share. Revenue: US$29.7m (down 28% from 1Q 2021). Net loss: US$30.0m (loss widened 20% from 1Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 9.0%, compared to a 48% growth forecast for the industry in the US.
Reported Earnings • Mar 19Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$1.85 loss per share (down from US$1.67 loss in FY 2020). Revenue: US$120.2m (down 17% from FY 2020). Net loss: US$192.0m (loss widened 35% from FY 2020). Products in clinical trials Phase I: 5 Phase II: 1 Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 43%. Over the next year, revenue is expected to shrink by 4.4% compared to a 64% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$32.3m (down 9.0% from 3Q 2020). Net loss: US$36.1m (loss narrowed 2.0% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$21.9m (down 45% from 2Q 2020). Net loss: US$34.3m (loss narrowed 15% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
공시 • Aug 18+ 1 more updateAthenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring OfficerAthenex, Inc. announced that on August 11, 2023, Joe Annoni, Chief Financial Officer and Assistant Chief Restructuring Officer of the company, and the Company mutually agreed that Mr. Annoni would separate from the Company effective immediately.
공시 • Jul 08Nasdaq to Delist the Common Stock of AthenexNasdaq also announced on July 06, 2023 that it will delist the common stock of Athenex, Inc. The company’s securities were suspended on April 13, 2023, and have not traded on Nasdaq since that time.
공시 • May 26Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite IndexAthenex, Inc. has been dropped from NASDAQ Composite Index.
공시 • May 25Athenex, Inc. announced delayed 10-Q filingOn 05/23/2023, Athenex, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 24Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 CaseOn May 16, 2023, Athenex, Inc. received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, as a result of the Chapter 11 Case and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Nasdaq staff determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on May 25, 2023.
공시 • May 18Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI IndexAthenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index
공시 • May 15+ 2 more updatesMotion for Asset Sale Filed by Athenex, Inc.Athenex, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on May 14, 2023. The debtor seeks the Court’s approval for the sale of its substantially all its assets to the stalking horse bidder. The debtor shall designate stalking horse bidder on June 2, 2023. To qualify as a qualified bidder, interested parties should submit their bids by June 12, 2023, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.10 million more than the initial purchase price. The debtor has scheduled an auction on June 15, 2023. At the auction, the subsequent bids would be in increments of $0.1 million. The stalking horse bidder would be entitled to a break-up fee of 3% of the cash portion of the purchase price and expense reimbursement of 1% of the cash portion of the purchase price in case of termination of the asset purchase agreement. The sale hearing is scheduled for June 21, 2023. Sale closing shall occur on June 30, 2023
공시 • May 05Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)On April 27, 2023, Athenex, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days and its number of publicly held shares, the Company no longer meets Nasdaq Listing Rule 5450(b)(3)(C), which requires listed companies to maintain a minimum market value of publicly held shares of at least $15 million. Nasdaq Listing Rule 5810(c)(3)(D) provides a compliance period of 180 calendar days, or until October 24, 2023, in which to regain compliance with this requirement. If the Company’s market value of publicly held shares is $15 million or more for a minimum of 10 consecutive business days during the 180-day compliance period, Nasdaq will provide written notice of compliance to the Company. If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The notification has no immediate effect on the listing of the Company’s common stock on Nasdaq’s Global Select Market. The Company intends to monitor the closing bid price of its common stock and its number of publicly held shares and consider its available options in the event the market value of its publicly held shares remains below $15 million.
공시 • Feb 17Athenex Announces Reverse Stock SplitAthenex, Inc. announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. The Company's Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of The Nasdaq Global Select Market. The Company has until March 14, 2023 to comply with this requirement. To evidence compliance with this requirement, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days by March 14, 2023. The Company's shares of common stock will continue to trade on The Nasdaq Global Select Market under the symbol "ATNX." The new CUSIP number for the Company's common stock post-reverse stock split is 04685N202.
공시 • Jan 04Athenex Announces MHRA Decision on Oral PaclitaxelAthenex, Inc. announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for metastatic breast cancer based solely on CMC issues. The MHRA application was not rejected based on any clinical efficacy or safety concerns expressed by the MHRA. MHRA regulations allow an applicant to request a re-examination of an opinion by an independent board which the Company plans to pursue. The Company views the identified CMC issues as addressable.
Price Target Changed • Nov 16Price target decreased to US$2.17Down from US$2.33, the current price target is an average from 3 analysts. New target price is 965% above last closing price of US$0.20. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$0.66 next year compared to a net loss per share of US$1.85 last year.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 04Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.14 loss per share (improved from US$0.33 loss in 3Q 2021). Revenue: US$33.5m (up 3.8% from 3Q 2021). Net loss: US$19.4m (loss narrowed 46% from 3Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 6.7%. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
Seeking Alpha • Aug 11Athenex prices $30M in stock and warrants offeringAthenex (NASDAQ:ATNX) plunged 23.9% down premarket after it priced its underwritten public offering of 35.3M shares and accompanying warrants at a combined public offering price of $0.75/share and accompanying warrant, pre-funded warrants to purchase up to 4.67M shares at a combined public offering price of $0.749/share and accompanying warrant. Gross proceeds are expected to be ~$30M. Offer is expected to close on Aug.15, 2022. Net proceeds was used to fund ongoing clinical development for its product candidates and for working capital and other general corporate purposes.
Seeking Alpha • Aug 05Athenex surges 70% as Dr Reddy's and Intas race to form buyout dealThe shares of Athenex Inc. (NASDAQ:ATNX) climbed ~70% on rising volumes in the post-market Thursday in reaction to reports that India's Dr. Reddy's Laboratories (RDY) and Intas Pharmaceuticals are in talks to acquire the cancer-focused biotech. The companies are competing against several mid-market healthcare-focused U.S. private equity funds to strike a deal as the biotech looks to sell a controlling stake, India's The Economic Times newspaper reported citing people with knowledge of the matter. The clinical-stage biotech is said to have named Cowen to lead a formal process to find an acquirer. "A formal process has started, and the first round of offers have come in," one of the people said. "Intas and Dr. Reddy's are the two Indian firms in the race at present. A transaction could be concluded during the current quarter." Athenex (ATNX) is the latest biotech to generate reports of buyout interest on Thursday. Before the market open, Amgen (AMGN) announced an agreement to acquire ChemoCentryx (CCXI) for $3.7B in cash.
Reported Earnings • Jul 28Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)Second quarter 2022 results: US$0.21 loss per share (up from US$0.33 loss in 2Q 2021). Revenue: US$31.5m (up 44% from 2Q 2021). Net loss: US$23.8m (loss narrowed 31% from 2Q 2021). Over the next year, revenue is forecast to grow 8.2%, compared to a 40% growth forecast for the industry in the US.
Seeking Alpha • Jul 28Athenex GAAP EPS, revenue misses estimatesAthenex press release (NASDAQ:ATNX): Q2 GAAP EPS of -$0.28 misses by $0.13. Revenue of $25.79M (+17.7% Y/Y) misses by $5.47M. Shares +5% PM. Athenex continues to expect product sales from continuing operations growth to be in the range of 20-25% over the prior year period.
Seeking Alpha • Jul 11Athenex to sell its China API business for $19MAthenex (NASDAQ:ATNX) and certain affiliates to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient (API) manufacturing operations, to TiHe Capital Co., Ltd. for RMB 124.4 million, or ~$19M. Athenex will receive at least 70% of the proceeds at closing, followed by 20% within three months after the closing date, and the remaining balance within six months after the closing date. The proceeds will be used in part toward repaying existing debt and operating the business. The deal is subject to customary closing conditions Athenex and TiHe also plan to enter into a long-term supply agreement for the manufacture and supply of certain API products. The company continues to monetize non-core assets to extend cash runway. ATNX --3.1563845% after hours to $0.54 Source: Press Release
Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.16 loss per share. Revenue: US$29.7m (down 28% from 1Q 2021). Net loss: US$30.0m (loss widened 20% from 1Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 9.0%, compared to a 48% growth forecast for the industry in the US.
Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Apr 27Price target decreased to US$4.50Down from US$5.25, the current price target is an average from 5 analysts. New target price is 765% above last closing price of US$0.52. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$0.49 next year compared to a net loss per share of US$1.85 last year.
Price Target Changed • Apr 13Price target decreased to US$4.50Down from US$5.40, the current price target is an average from 4 analysts. New target price is 552% above last closing price of US$0.69. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$0.51 next year compared to a net loss per share of US$1.85 last year.
Major Estimate Revision • Mar 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$135.3m to US$114.9m. EPS estimate increased from -US$1.01 to -US$0.55 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$6.25 to US$5.50. Share price rose 16% to US$0.99 over the past week.
Reported Earnings • Mar 19Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$1.85 loss per share (down from US$1.67 loss in FY 2020). Revenue: US$120.2m (down 17% from FY 2020). Net loss: US$192.0m (loss widened 35% from FY 2020). Products in clinical trials Phase I: 5 Phase II: 1 Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 43%. Over the next year, revenue is expected to shrink by 4.4% compared to a 64% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 18Price target decreased to US$5.50Down from US$6.25, the current price target is an average from 4 analysts. New target price is 479% above last closing price of US$0.95. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$1.85 last year.
Price Target Changed • Feb 24Price target increased to US$6.67Up from US$5.60, the current price target is an average from 3 analysts. New target price is 726% above last closing price of US$0.81. Stock is down 93% over the past year. The company is forecast to post a net loss per share of US$1.34 next year compared to a net loss per share of US$1.72 last year.
Recent Insider Transactions • Nov 20Independent Director recently bought US$61k worth of stockOn the 17th of November, Jinn Wu bought around 30k shares on-market at roughly US$2.03 per share. In the last 3 months, they made an even bigger purchase worth US$161k. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$32.3m (down 9.0% from 3Q 2020). Net loss: US$36.1m (loss narrowed 2.0% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 15Independent Director recently bought US$161k worth of stockOn the 14th of September, Jinn Wu bought around 50k shares on-market at roughly US$3.22 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.
Seeking Alpha • Aug 31Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers. Athenex's pipeline consists of four therapeutic programs, Orascovery (P-glycoprotein pump inhibitor), Src Kinase Inhibition, Cell Therapy, and Arginine Deprivation Therapy. Athenex's lead therapeutic is Klisyri (tirbanibulin) launched in the US in Feb 2021 with an EU launch expected in 2H’21 under a partnership with Almirall. Athenex received a CRL from the FDA in Feb'21 for Oral paclitaxel + encequidar's and now Athenex is planning a new study design expected to be presented in 4Q 2021. In summary, the author projects Athenex, Inc. as a "hold".
Executive Departure • Aug 18Chief Financial Officer Randoll Sze has left the companyOn the 13th of August, Randoll Sze's tenure as Chief Financial Officer ended after 3.0 years in the role. As of June 2021, Randoll still personally held only 6.00k shares (US$28k worth at the time). Randoll is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.42 years.
Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$21.9m (down 45% from 2Q 2020). Net loss: US$34.3m (loss narrowed 15% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 06Consensus EPS estimates fall to -US$1.31The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from US$124.5m to US$120.9m. Losses expected to increase from -US$1.14 to -US$1.31. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$7.95 to US$7.33. Share price fell 4.5% to US$3.60 over the past week.
Price Target Changed • Jul 07Price target decreased to US$7.50Down from US$8.67, the current price target is an average from 8 analysts. New target price is 86% above last closing price of US$4.03. Stock is down 70% over the past year.
Reported Earnings • May 11First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$41.0m (down 13% from 1Q 2020). Net loss: US$25.1m (loss widened 29% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Recent Insider Transactions Derivative • May 07Independent Director exercised options to buy US$230k worth of stock.On the 5th of May, Jinn Wu exercised options to buy 50k shares at a strike price of around US$4.55, costing a total of US$228k. This transaction amounted to 16% of their direct individual holding at the time of the trade. Since June 2020, Jinn's direct individual holding has decreased from 371.21k shares to 303.21k. Company insiders have collectively sold US$342k more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • May 07Consensus EPS estimates increase to -US$1.42The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$115.2m to US$120.9m. EPS estimate increased from -US$1.74 to -US$1.42. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target of US$8.67 unchanged from last update. Share price rose 15% to US$4.60 over the past week.
분석 기사 • Apr 04Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Recent Insider Transactions Derivative • Mar 20Chairman & CEO exercised options to buy US$98k worth of stock.On the 19th of March, Yiu-Nam Lau exercised options to buy 20k shares at a strike price of around US$4.55, costing a total of US$91k. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since March 2020, Yiu-Nam's direct individual holding has increased from 3.28m shares to 3.33m. Company insiders have collectively sold US$380k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Mar 11Insider recently sold US$1.9m worth of stockOn the 4th of March, Wei Zuo sold around 420k shares on-market at roughly US$4.52 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$560k more than they bought in the last 12 months.
분석 기사 • Mar 09Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?Some Athenex, Inc. ( NASDAQ:ATNX ) shareholders may be a little concerned to see that insider Wei Zuo recently sold a...
Major Estimate Revision • Mar 08Analysts lower revenue estimates to US$115.2mThe 2021 consensus revenue estimate decreased from US$178.3m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.18 to -US$1.47 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 4.8% next year. The consensus price target was lowered from US$27.41 to US$10.00. Share price is down by 64% to US$4.32 over the past week.
분석 기사 • Mar 06These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS ForecastsOne thing we could say about the analysts on Athenex, Inc. ( NASDAQ:ATNX ) - they aren't optimistic, having just made a...
Recent Insider Transactions • Mar 05Independent Director recently sold US$466k worth of stockOn the 3rd of March, Jinn Wu sold around 98k shares on-market at roughly US$4.75 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$1.9m more than they sold in the last 12 months.
Reported Earnings • Mar 03Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$144.4m (up 43% from FY 2019). Net loss: US$146.2m (loss widened 18% from FY 2019). Post-clinical trial products Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 03Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 5.8%. Earnings per share (EPS) also surpassed analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 4.0% compared to a 1,173% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Mar 02New 90-day low: US$5.46The company is down 59% from its price of US$13.30 on 01 December 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$80.60 per share.
Price Target Changed • Mar 02Price target lowered to US$24.78Down from US$27.74, the current price target is an average from 9 analysts. The new target price is 354% above the current share price of US$5.46. As of last close, the stock is down 58% over the past year.
분석 기사 • Feb 19Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
분석 기사 • Jan 29When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?With the business potentially at an important milestone, we thought we'd take a closer look at Athenex, Inc.'s...